http://jcps.bjmu.edu.cn

• 研究论文 • 上一篇    下一篇

硝苯地平缓释片人体药代动力学研究

武静, 王本杰, 魏春敏, 卜凡龙, 郭瑞臣*   

  1. 山东大学齐鲁医院 临床药理研究所, 济南 250012
  • 收稿日期:2006-12-15 修回日期:2007-08-10 出版日期:2007-09-15 发布日期:2007-09-15
  • 通讯作者: 郭瑞臣*

Pharmacokinetics of nifedipine sustained-release tablets in healthy Chinese volunteers

Jing Wu, Ben-Jie Wang, Chun-Min Wei, Fan-Long Bu, Rui-Chen Guo*   

  1. Institute of Clinical Pharmacology, Qilu Hospital of Shandong University, Jinan 250012, China
  • Received:2006-12-15 Revised:2007-08-10 Online:2007-09-15 Published:2007-09-15
  • Contact: Rui-Chen Guo*

摘要: 目的 建立HPLC-MS法硝苯地平血浓度测定方法, 评价硝苯地平缓释片的药动学特点。方法 固定相XB-C18 (5μm,150 mm × 4.6 mm, Agilent 1100 Series LC/MSD 高效液相色谱/质谱仪; 流动相甲醇: 0.01 mol·L-1醋酸铵溶液(60:40, V/V), 0.40 微孔滤膜过滤, 在线脱气; 流速1.0 mL·min-1; 柱温25 ºC; 进样量10 L。离子源:AP-ESI, 正离子模式, 雾化电压50 psi, 保护气13.0 L·min-1 N2, 毛细管电压4000V, 碎片电压为110VSIM离子采集方式, 采集离子(m/z) 硝苯地平314.9[M+H]+, 内标劳拉西泮320.8 [M+H]+结果 硝苯地平线性范围0.380 ng·mL-1, 最低检出浓度为0.3 ng·mL-1。硝苯地平试验制剂和参比制剂t1/2分别为6.73 ± 2.00 h7.04 ± 2.18 h, Tmax分别为4.28 ± 0.70 h4.48 ± 0.70 h, Cmax分别为39.66 ± 10.58 ng·mL-1 40.19 ± 10.97 ng·mL-1, AUC036分别为391.63 ± 108.55 ng·mL-1·h 387.57 ± 121.51 ng·mL-1·h, AUC0-分别为408.28 121.16 ng·mL-1·h406.15 ± 133.13 ng·mL-1·h, 试验制剂硝苯地平缓释片相对生物利用度F103.02 13.93%结论 HPLC-MS法测定硝苯地平血浓度实用、可行, 适用于常规硝苯地平药代动力学研究。

关键词: 硝苯地平缓释片, 硝苯地平缓释片, 硝苯地平缓释片, 液相色谱/质谱联用, 液相色谱/质谱联用, 液相色谱/质谱联用, 药动学, 药动学, 药动学, 生物等效性, 生物等效性, 生物等效性

Abstract:

Aim To establish a LC-MS method for determining the concentration of nifedipine in human plasma and to evaluate the pharmacokinetic characteristics of nifedipine sustained-release tablets. Methods A XB-C18 (5 μm, 4.6 mm × 150 mm) column and a mobile phase of methanol: 0.01 mol·L-1 ammonium acetate (60:40, V/V) were used to separate nifedipine, the detections was accuracy under atmosperic pressure electronic spray ionization (AP-ESI) mode and ion mass spectrum (m/z) of 314.9[M+H]+ for nifedipine, and 320.8 [M+H]+ for lorazepam (Internal Standard, IS). Results The linear range of nifedipine was 0.3 – 80 ng·mL-1 ( r = 0.9997), and the limit of quantitation (LOQ) was 0.3 ng·mL-1. The nifedipine pharmacokinetic parameters after a single dose of 20 mg nifedipine sustained-release tablets test (T) or reference (R) were as the followings, t1/2 (6.73 ± 2.00) h and (7.04 ± 2.18) h, Tmax (4.28 ± 0.70) h and (4.48 ± 0.70) h, Cmax (39.66 ± 10.58) ng·mL-1 and (40.19 ± 10.97) ng·mL-1, AUC0-36 (391.63 ± 108.55) ng·mL-1·h and (387.57 ± 121.51) ng·mL-1·h, and AUC0- (408.28 ± 121.16) ng·mL-1·h and (406.15 ± 133.13) ng·mL-1·h. The relative bioavailability of nifedipine sustained-release tablets (test) was (103.02 ± 13.93) %. Conclusion LC-MS method for the determination of concentrations of nifedipine in human plasma was sensitive and accurate, and could be used in nifedipine bioavailability and pharmacokinetic studies.

Key words: Nifedipine sustained-release tablets, Nifedipine sustained-release tablets, LC-MS, LC-MS, Pharmacokinetics, Pharmacokinetics, Bioequivalence, Bioequivalence

中图分类号: 

Supporting:

*Corresponding author. Tel.: 86-531-82169636